Neuroscience

Researcher in a medical lab
#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Predict disease risk long before diagnosis

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK government

DDW Highlights: 3 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere,… Read More

#Podcasts

#Allergy #Biomarkers #Biotech #Breast cancer #Europe #HER2 #Immune cells #Neurology #Oncology #Pancreatic cancer #Parkinson's #Therapeutic targets #Tokyo University of Science #Tumour microenvironment (TME) #UK #UK government

This week in Drug Discovery (26 – 30 January) 

News round-up for 26 – 30 January by Bruno Quinney, Content Team at DDW.  This week in DDW, discoveries into Parkinson’s disease, allergies and common cancers could shape drug development. Elsewhere, why is the UK leading Europe’s biotech market? The top stories:    Parkinson’s could be identified in… Read More

#News

Neuroscience Parkinson's disease
#Neurology #Norway #Parkinson's #Sweden

Parkinson’s could be identified in the blood, study shows 

Early signs of Parkinson’s disease can be identified in the blood, new research suggests.  In a new study published in npj Parkinson’s Disease, a research team from Chalmers University of Technology, Sweden and Oslo University Hospital, Norway identified biomarkers for Parkinson’s disease in its earliest stages, before extensive brain damage has occurred. Read More

#News

#Biomarkers #Drug discovery #Parkinson's #Protein chemistry / Proteomics #Webinar

Webinar: Mapping disease trajectories with proteomics

What if you could see diseases like Parkinson’s coming years before symptoms appear? In this webinar, hosted by DDW and supported by Standard BioTools, Benoit Lehallier, PhD, Senior Director, Data Science at Alkahest will share how SomaScan Technology, alongside complementary proteomic platforms, uncovers signals that predict disease risk… Read More

Webinar date:
Supported by Standard BioTools
#News

#AI / data analytics / healthtech / informatics #Antibodies #Biotech #Drug discovery #GLP-1 #IPO #Mergers and acquisitions #Neuroscience

JPM 2026: Less talk and more action 

‘JPM 2026’ certainly felt different to recent editions of the conference. The sky was blue – and the XBI had nearly doubled over the previous nine months.  There’s nothing like a little winter sun and booming stocks to put a spring in an executive’s step!  But questions over the robustness of the biopharma… Read More

#Exclusive Content

Antibodies
#Alzheimer's #Neuroscience #Novartis #SciNeuro Pharmaceuticals #Therapeutic Antibodies

Novartis and SciNeuro collaborate on antibodies for Alzheimer’s

Novartis Pharma and SciNeuro Pharmaceuticals have agreed a worldwide licensing and collaboration agreement to advance SciNeuro’s novel amyloid beta targeted antibody programme for the treatment of Alzheimer’s disease.    The programme has identified de novo antibody candidates that incorporate SciNeuro’s proprietary blood brain barrier shuttle technology… Read More

#Business & Investment #News

Neurons
#Amyotrophic lateral sclerosis (ALS) #MND #Neuroscience #NRG Therapeutics #Phase I trial

Disease-modifying treatment for ALS enters Phase I

The first participants have been dosed in the first-in-human Phase I clinical trial of NRG Therapeutics’ lead candidate NRG5051, which is being developed as a treatment for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) and Parkinson’s.   NRG5051 is a first-in-class, orally bioavailable and CNS-penetrant next-generation inhibitor of the mitochondrial… Read More

#News #Trending News

Node structures in the central nervous system
#Alzheimer's #Biotech #CNS #Insilico Medicine #Parkinson's

Insilico and Hygtia Therapeutics partner on CNS disease drug 

Biotechnology companies Insilico Medicine and Hygtia Therapeutics have announced a co-development collaboration agreement for Insilico’s ISM8969.  The partnership will look to accelerate the global advancement of ISM8969, an orally available, brain penetrant NLRP3 inhibitor for Central Nervous System (CNS) disorders.   The NLRP3 inflammasome is a critical component of the innate immune system but… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Alzheimer's #Drug discovery #Oncology #Regulatory #Spatial biology

DDW Winter issue out now

The DDW Winter 2025/2026 issue is out now and includes features covering the advances and challenges in blood cancer drug development, how the Baltics is implementing a new action plan for its life sciences sectors, and how spatial epigenetics is unlocking new frontiers for drug discovery.  It also… Read More

#News

#Antidepressants #Depression #Drug targets #Korea University #Major depressive disorder #Neuroscience

New evidence revives abandoned depression drug target

New research has revealed that structurally novel neurokinin-1 receptor (NK1R) inhibitors reduce depressive-like behaviour and brain inflammation in mice.  For decades, scientists have investigated the NK1R as a potential target for treating major depressive disorder. Early studies suggested promise, but enthusiasm faded after clinical trials of drugs… Read More

#Editor's Choice #Editor's Pick #News

Lilly Biotechnology Center
#Acute inflammatory conditions #Cardiometabolic diseases #Eli Lilly #Mergers and acquisitions #Neurodegenerative disorders #Ventyx Biosciences

Lilly acquires Ventyx Biosciences for $1.2 billion

Eli Lilly has agreed to acquire Ventyx Biosciences, a clinical-stage biopharmaceutical company focused on developing oral therapies for patients with inflammatory-mediated diseases.  Ventyx is developing a pipeline of small molecule therapeutics, including NLRP3 inhibitors, designed to treat inflammation across a broad range of disease states with high… Read More

#Business & Investment #News

#ALS #Fast Track designation #FDA

FDA grants Fast Track Designation to ALS treatment 

The US Food and Drug Administration (FDA) has granted Fast Track Designation to a first-in-class vectorised antibody for the treatment of amyotrophic lateral sclerosis (ALS).  VTx-002, developed by biotechnology company VectorY Therapeutics, targets TDP-43 pathology, which drives up to 97% of ALS cases.  Fast Track is a process designed… Read More

#News #Regulatory

Neurodegenerative disorders
#Financing #Metabolic diseases #Neurodegenerative disorders #Novel therapeutics

Soley Therapeutics raises $200m to advance oncology leads 

Biotechnology company Soley Therapeutics has raised $200 million Series C financing to advance its proprietary cell stress sensing platform and pipeline of novel therapeutics into clinic.  It is believed Soley intends to use the funds to support its work filing investigational new drug (IND) applications and its… Read More

#Business & Investment #News

#Cell and gene therapy #Gene editing #Immunotherapy #Neurodegenerative disorders #Obesity #Oncology

Which drug discovery breakthroughs made the headlines in 2025?

Diana Turner counts down the biggest DDW news stories of 2025.  10. First use of CAR-T therapy to treat ulcerative colitis In October, a team of physicians at the German Center for Immunotherapy at Erlangen University Hospital succeeded for the first time in treating a… Read More

#Exclusive Content

#Antisense Oligonucleotides (ASOs) #CAMP4 Therapeutics #Collaboration #GSK #Kidney disease #Neurodegenerative disorders

CAMP4 and GSK advance RNA-based therapeutic discoveries

GSK and CAMP4 Therapeutics have entered into a strategic research, collaboration and license agreement to identify and develop antisense oligonucleotide (ASO) drug candidates for multiple gene targets relevant to neurodegenerative and kidney disease indications.  “Protein under-expression plays a critical role in diseases such as neurodegenerative and kidney… Read More

#Business & Investment #News